AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16279894
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection (0.5 cc/quadrant triamcinolone 40 mg/cc)
Trial: 2050230
Drug: Topical retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoic acid 0.01%, 0.025%, or 0.05% applied for 10 days
Trial: 2050230
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of triamcinolone acetonide 0.1% and retinoic acid 0.025%
Trial: 6342544
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of salbutamol (inhalational powder and tablets)
Trial: 6342544
Drug: Tablet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet treatment of salbutamol
Trial: 6342544
Drug: Inhalational powder
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalational powder treatment of salbutamol
Trial: 6342544
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of salbutamol
Trial: 6342544
Drug: Combined or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined or tablet treatment of salbutamol
Trial: 22234381
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of risperidone
Trial: 17413949
Drug: Eyelid hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eyelid hygiene once daily
Trial: 30180918
Drug: Oxytocin (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (36 IU BID, supervised administration 45 min prior to CBSST sessions)
Trial: 24444140
Drug: Brief psychodynamic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychodynamic psychotherapy (eight sessions administered at two-week intervals)
Trial: 24444140
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (clinical interview, neurological examination, counselling, symptomatic therapy)
Trial: 16331769
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac diethylamine gel, 1.16%, 4 g applied qid for 3 weeks
Trial: 11964340
Drug: Training package
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training package of four half days on brief cognitive behaviour therapy
Trial: 2499178
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy plus intradermal immunization with viral oncolysate (VO)
Trial: 1138642
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low-dose heparin and hydrocortisone
Trial: 7378674
Drug: Iotroxamide infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iotroxamide infusion at rates of 0.525 to 6.3 mg/kg/min
Trial: 7378674
Drug: Iotroxamide infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iotroxamide infusion at an optimal rate of around 4 mg/kg/min
Trial: 26269566
Drug: l-alanyl-l-glutamine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-alanyl-l-glutamine (8 g/d) and polyunsaturated fatty acid (6.5 g/d)
Trial: 19856790
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of cetirizine hydrochloride
Trial: 11154482
Drug: Topical pharyngeal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pharyngeal anesthesia
Trial: 9663180
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day oral fluconazole
Trial: 3146891
Drug: L-5-hydroxytryptophan (L-5HTP)
RxNorm normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (L-5HTP)
Trial: 24078554
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 1 mg·kg(‐1)
Trial: 19673614
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg twice daily for 4 days
Trial: 29932413
Drug: 0.5-mg DuvieTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg DuvieTM tablets (test drug)
Trial: 29932413
Drug: 0.5-mg DuvieTM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5-mg DuvieTM tablets (reference drug)
Trial: 10619929
Drug: Duraflo II
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraflo II heparin-coated cardiopulmonary bypass circuits
Trial: 1826237
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of unmodified insulin (10 U)
Trial: 1826237
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of unmodified insulin (10 U)
Trial: 7122669
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg valerian extract
Trial: 2371367
Drug: Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5 mg)
Trial: 24576515
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen 6 L/min delivered by Oxymask for 6 to 12 hours
Trial: 22569622
Drug: ETT intracuff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETT intracuff 2% lidocaine plus 8.4% sodium bicarbonate (L group)
Trial: 20385439
Drug: Posterior maxilla
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior maxilla implants without sinus lift
Trial: 19238877
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (0.4 mg/day) starting at least one month before conception and continuing for the first quarter of pregnancy
Trial: 1901808
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ponalrestat
Trial: 7179208
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of heparin (i.v.)
Trial: 7179208
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (s.c.)
Trial: 24267731
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg/day
Trial: 26917112
Drug: DRV/r 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DRV/r 800/100 mg once daily
Trial: 21149923
Drug: LPV/r 800/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/r 800/200 mg total daily dose
Trial: 12126926
Drug: Pentaspan (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaspan (500 ml, infusion condition)
Trial: 12126926
Drug: Placebo (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (60 ml saline, non-infusion condition)
Trial: 3017596
Drug: Domperidone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (20 mg)
Trial: 30672192
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy combined with acupuncture (Baihui, Sishencong, Neiguan, Hegu, Taixi), treatment given once daily, 6 times a week for 4 weeks.
Trial: 30672192
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy only, treatment given once daily, 6 times a week for 4 weeks.
Trial: 17920108
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy using cisplatin/cyclophosphamide or cisplatin/paclitaxel chemotherapy
Trial: 27228432
Drug: SHAM treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHAM treatment, n=33
Trial: 23131255
Drug: Low-dose linezolid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose linezolid treatment for MDR-TB (16 weeks, daily dosage)
Trial: 31829925
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of atorvastatin (20 mg)
Trial: 31829925
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of atorvastatin (20 mg)
Trial: 20678686
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of ortho-hydroxy-atorvastatin (20 mg)
Trial: 20678686
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of ortho-hydroxy-atorvastatin (20 mg)
Trial: 17660388
Drug: Systemic infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic infusion of L-NMMA (10 mg/kg)
Trial: 15711037
Drug: Heparin-protamine (HP)
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-protamine (HP) post-filter
Trial: 15547086
Drug: DHEA 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 200 mg/day
Trial: 11254817
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate
Trial: 23891440
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet enriched with β-hydroxy-β-methylbutirate, calcium, and vitamin D administered during 30 days of hospitalization.
Trial: 23891440
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet administered during 30 days of hospitalization.
Trial: 12637119
Drug: Choline alfoscerate
RxNorm normalized name: Choline Alfoscerate
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline alfoscerate (CA) 400 mg capsules, 3 times daily for 180 days
Trial: 3933134
Drug: 10% mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% mannitol mechanical bowel preparation combined with oral neomycin and short-term, perioperative intravenous Flagyl (group I)
Trial: 31064779
Drug: low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose cytarabine (LDAC) alone
Trial: 29050507
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment (Control Group)
Trial: 16980507
Drug: LNG +
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LNG + Meloxicam (Melox) 15 mg
Trial: 7007840
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy with cimetidine (400 mg twice a day)
Trial: 7007840
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy with cimetidine (six-week courses for each relapse)
Trial: 27893326
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and pemetrexed (platinum therapy)
Trial: 27893326
Drug: Paclitaxel and
RxNorm normalized name: paclitaxel and encequidar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel and pemetrexed (nonplatinum therapy)
Trial: 25778467
Drug: GIK infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIK infusion for 12 hours
Trial: 16249701
Drug: Lopinavir/ritonavir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir + 2 nucleosides (triple therapy)
Trial: 12072676
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of positive ions for 4 hrs followed by inhalation of air from a home humidifier generating O(2)(‐)(H(2)O)(n) for 4 hrs
Trial: 30208421
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy (delivered via a light-emitting mask, peak 505 nm, 23 scotopic Td), worn each night for 12 months
Trial: 24178368
Drug: Vemurafenib 480
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 480 mg bid
Trial: 24178368
Drug: Vemurafenib 720
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 720 mg bid
Trial: 24178368
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg bid
Trial: 21760473
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg once daily
Trial: 15868131
Drug: Subjective roughness
RxNorm normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjective roughness scaling by 19 speech and voice therapy students
Trial: 27836677
Drug: NEMEX therapy
RxNorm normalized name: Nemex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEMEX therapy (neuro-muscular exercise) twice a week for 8 weeks
Trial: 27836677
Drug: NEMEX therapy
RxNorm normalized name: Nemex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEMEX therapy and PHARMA
Trial: 23415779
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative treatment regimen without topical cyclosporine A
Trial: 19154960
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin E, 800 IU; vitamin C, 500 mg; beta-carotene, 10 mg)
Trial: 16776335
Drug: Gamma knife
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma knife surgery to the retrogasserian cisternal portion of the fifth cranial nerve, median dose 85 Gy (range 70‐90 Gy)
Trial: 11316215
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg p.o. b.i.d. for 3 months
Trial: 7895895
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg low-molecular-weight dermatan sulphate
Trial: 7895895
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg low-molecular-weight dermatan sulphate
Trial: 7895895
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg and 200 mg low-molecular-weight dermatan sulphate
Trial: 23765237
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy after invasive mechanical ventilation (RRT after IMV)
Trial: 14731181
Drug: Vertical Guided
RxNorm normalized name: Verticalm
DrugBank: Meclizine (DB00737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vertical Guided Bone Regeneration (GBR) with autogenous bone and e-PTFE membranes; 25 implants placed.
Trial: 14731181
Drug: Distraction Osteogenesis
RxNorm normalized name: Osteogenic protein 1
DrugBank: Eptotermin alfa (DB11631)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Distraction Osteogenesis (DO); 34 implants placed.
Trial: 18655559
Drug: Cuichan Zhusheng
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuichan Zhusheng Decoction (CZD), 300 mL daily, taken orally for 3 days
Trial: 18655559
Drug: Pitocin, 1
RxNorm normalized name: Pitocin, 10 units/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitocin, 1 U into 500 mL 5% glucose for intravenous dripping for 3 days
Trial: 2894181
Drug: Temazepam 10
RxNorm normalized name: temazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam 10 mg
Trial: 21545399
Drug: naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxcinod 750 mg twice daily
Trial: 9626829
Drug: Eptifibatide therapy
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide therapy
Trial: 1460170
Drug: Global self‐ratings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Global self‐ratings administered twice a day
Trial: 1460170
Drug: Itemized, prospective,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itemized, prospective, observer‐rated scale administered twice a day
Trial: 27541314
Drug: Smartphone-delivered maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-delivered maintenance intervention based on acceptance and commitment therapy (ACT)
Trial: 20204974
Drug: CAD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAD plus an additional four-session self-management group training (CAD+G, n = 31)
Trial: 16225490
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 40 mg
Trial: 16225490
Drug: Oral esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral esomeprazole 40 mg
Trial: 16225490
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole 20 mg
Trial: 16225490
Drug: Oral esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral esomeprazole 20 mg
Trial: 15674097
Drug: Intravenous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous esomeprazole (both dosages)
Trial: 8576661
Drug: Furosemide 1
RxNorm normalized name: furosemide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 1 mg/kg immediate preoperation
Trial: 1970960
Drug: Plain tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain tablets (500 mg theophylline)
Trial: 394795
Drug: Baclofen 5
RxNorm normalized name: baclofen 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 5 mg qds
Trial: 21458191
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin daily for 5 years
Trial: 19353539
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g fenugreek fiber
Trial: 19353539
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g fenugreek fiber
Trial: 19353539
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g fenugreek fiber (control)
Trial: 17509194
Drug: Letrozole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 7.5 mg
Trial: 14980901
Drug: Desmopressin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin 0.3 micro g/kg
Trial: 8516091
Drug: Calf lung
RxNorm normalized name: Calf lung surfactant extract (CLSE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf lung surfactant extract (CLSE) administered at birth
Trial: 8516091
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (control group)
Trial: 3436153
Drug: Hydrochlorothiazide/triamterene (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide/triamterene (25 mg/50 mg)
Trial: 26537944
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g pure whey protein isolate (L)
Trial: 16563324
Drug: TIVA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA group (propofol 2.0 mg/kg intravenously by bolus injection and fentanyl 2 microg/kg for induction; propofol 5 mg/kg per hour for maintenance)
Trial: 19302581
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 7.5 mg/month
Trial: 19302581
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 22.5 mg every 3 months
Trial: 19302581
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (7.5 mg, 11.25 mg, 22.5 mg)
Trial: 2645824
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers (metoprolol and propranolol)
Trial: 788760
Drug: Brolitene (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolitene (1200 mg per day, 6 tablets)
Trial: 30566641
Drug: Water supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water supplementation (1.5 L daily for 6 weeks)
Trial: 28660719
Drug: Participants not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants not using insulin in the intervention group